Mohamed Sorror, MD, MSc

Dr. Mohamed Sorror’s research is dedicated to improving the care of patients with aggressive blood cancers who also have health vulnerabilities including being of older age, frail or with multiple other medical problems. While most people with blood cancers are seniors, studies of new treatments for these diseases routinely exclude them. To solve this problem, Dr. Sorror is leading the field in gathering evidence and developing decision-making tools to guide the choice of the best treatment for vulnerable patients with blood cancers.

Dr. Sorror also leads a large, multi-center, randomized intervention trial testing novel approaches, such as supportive and palliative care, exercise training and dedicated management of individual comorbidities, for patients receiving stem cell transplants to treat blood cancers. This study and others are dedicated to improving the health of vulnerable patients with blood cancers so their outcomes after transplant or immunotherapy are closely similar to those of all other patients.

Through both clinical and population-based studies, Dr. Sorror aims to optimize the benefits of health care to patients and to society. For example, he is testing, developing and validating methods and tools to predict patient outcomes on treatment, including survival, toxicity and quality of life. He is learning patients’ experiences, preferences and values for cancer treatment. And his trials are generating evidence of which interventions work best for which types of patients and under what circumstances. Notably, he and colleagues developed the first scoring system, now used worldwide, for predicting the risks a blood stem cell transplant poses for a particular patient. Additionally, Dr. Sorror is leading efforts to enhance access of patients from underrepresented minorities or those with adverse socio-economic factors to the potentially curative therapies of stem cell transplantation and immunotherapy.